{"nctId":"NCT03440814","briefTitle":"A Study of Diazoxide Choline in Patients With Prader-Willi Syndrome","startDateStruct":{"date":"2018-05-09","type":"ACTUAL"},"conditions":["Prader-Willi Syndrome"],"count":127,"armGroups":[{"label":"DCCR","type":"EXPERIMENTAL","interventionNames":["Drug: DCCR"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo for DCCR"]}],"interventions":[{"name":"DCCR","otherNames":[]},{"name":"Placebo for DCCR","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Provide voluntary, written informed consent (parent(s) / legal guardian(s) of patient); provide voluntary, written assent (patients, as appropriate)\n* Genetically-confirmed Prader-Willi syndrome and hyperphagic\n* In a stable care setting for at least 6 months prior to Visit 1\n* Caregiver must have been caring for the patient for at least 6 months prior to Visit 1\n\nExclusion Criteria:\n\n* Have participated in an interventional clinical study (i.e., investigational drug or device, approved drugs or device evaluated for unapproved use) within prior 3 months\n* Positive urine pregnancy test (in females of child-bearing potential) or females who are pregnant or breastfeeding, and/or plan to become pregnant or to breast-feed during or within 30 days after study participation\n* Any other known disease and/or condition, which would prevent, in the opinion of the Investigator, the patient from completing all study visits and assessments required by the protocol","healthyVolunteers":false,"sex":"ALL","minimumAge":"4 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Hyperphagia Questionnaire (HQ-CT) Change From Baseline at Visit 7 (Week 13)","description":"Hyperphagia-related behaviors were assessed by the validated hyperphagia questionnaire for clinical trials (HQ-CT), an instrument designed to measure symptoms of food related preoccupations and behaviors that was completed by the caregiver. The HQ-CT consists of nine items with responses ranging from 0-4 units each (possible total score range: 0-36). The HQ-CT was assessed at Screening, Baseline (Visit 2), and approximately every 4 weeks post-dose at Week 4, Week 8, and Week 13. A decrease in score from baseline represented improvement.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.94","spread":"0.879"},{"groupId":"OG001","value":"-4.27","spread":"1.145"}]}]}]},{"type":"SECONDARY","title":"Clinical Global Impression of Improvement (CGI-I) at Visit 7 (Week 13)","description":"The Clinical Global Impression of Improvement (CGI-I) is a single statement designed to assess the Investigator's overall perception of change in the subject's condition across the course of the clinical trial. The Investigator provided a response to \"Compared to the subject's condition at enrollment, the subject's condition is:\" by rating the subject's behavior using a 7-point response scale: Very much improved, Much improved, Minimally improved, No change, Minimally worse, Much worse, and Very much worse. The Investigator only took into account the subject's PWS condition.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"2","spread":null}]},{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"37","spread":null}]},{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"3","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Caregiver Global Impression of Change (GI-C) at Visit 7 (Week 13)","description":"The Caregiver Global Impression of Change (GI-C) is a single statement designed to assess the caregiver's overall perception of change in the subject across the course of the clinical trial. The caregiver provided a response to \"Please choose the response below that best describes the overall change in the person's PWS since they started taking the study medication\" using a 7-point graded response scale: Very much better, Moderately better, A little better, No change, A little worse, Moderately worse, and Very much worse.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"1","spread":null}]},{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"3","spread":null}]},{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"8","spread":null}]},{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"20","spread":null}]},{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"5","spread":null}]},{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"3","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Fat Mass (kg) From Baseline at Visit 7 (Week 13)","description":"Whole body scans were performed. Reports included a breakdown of the following regions: left arm, right arm, trunk, left leg, right leg, and head. Each region was evaluated for body fat mass (g).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.80","spread":"0.356"},{"groupId":"OG001","value":"0.25","spread":"0.444"}]}]}]},{"type":"POST_HOC","title":"Hyperphagia Questionnaire (HQ-CT) Change From Baseline at Visit 7 (Week 13) - Pre-COVID Analysis","description":"Hyperphagia-related behaviors were assessed by the validated hyperphagia questionnaire for clinical trials (HQ-CT), an instrument designed to measure symptoms of food related preoccupations and behaviors that was completed by the caregiver. The HQ-CT consists of nine items with responses ranging from 0-4 units each (possible total score range: 0-36). The HQ-CT was assessed at Screening, Baseline (Visit 2), and approximately every 4 weeks post-dose at Week 4, Week 8, and Week 13. A decrease in score from baseline represented improvement.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.64","spread":"1.001"},{"groupId":"OG001","value":"-3.51","spread":"1.278"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":84},"commonTop":["Hypertrichosis","Oedema peripheral","Upper respiratory tract infection","Headache","Hyperglycaemia"]}}}